SFNS-UCSF Annual Aird Dinner

Thursday, October 6, 2016

Hyatt Regency Hotel
5 Embarcadero
San Francisco 94111

Eva L. Fedman, MD, PhD
"Stem Cell Therapy in ALS: Where We are Today"

Become A Member

Member Login

Meeting Registration
courtesy of pixabay

Dr. Feldman received her M.D. and Ph.D. degrees from the University of Michigan (U-M), completed a neurology residency at the Johns Hopkins Hospital and returned to U-M for a Neuromuscular fellowship. In addition to her active clinical practice in neurology and position as the Russell N. DeJong Professor of Neurology at the U-M Medical School, Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute, and is Director of Research for the U-M ALS clinic. She also runs her own 30-scientist laboratory, the Program for Neurology Research & Discovery, and is the principal investigator of two first-ever FDA approved human clinical trials of intraspinal stem cell implantation therapy for ALS. Dr. Feldman has published more than 350 original peer-reviewed articles, 60 book chapters and three books and has had continuous funding from the National Institutes of Health for more than 20 years.

She is Past President of the Peripheral Nerve Society and served as President of the American Neurological Association from 2011 to 2013, the third woman to hold this position in 130 years. Among Dr. Feldman’s greatest accomplishments is her training of both scientists and neurologists. Nine scientists have received their Ph.D. degrees under her supervision. She has trained 40 postdoctoral fellows in her laboratory to become neuroscientists, and 50 neurology fellows have trained under her to specialize in the treatment of neuromuscular and neurodegenerative diseases, with an emphasis on ALS and neuropathy.

In March of 2016, Dr. Feldman was honored as one of America’s Top Doctors, earning one of only three Clinical Excellence Awards at the 11th Annual National Physician of the Year Awards in New York. In June 2016, she was named among the 100 Most Influential Women in Michigan by Crain’s Detroit Business. In addition, she has received both the Early and Distinguished Career Development Awards from the U-M, a lifetime achievement award from the American Diabetes Association and was elected into both the Johns Hopkins Society of Scholars and the National Academy of Medicine.

Educational Objectives

1. Differentiate the various types of stem cells for therapeutic use in neurological disorders.

2. Examine the preclinical data supporting the therapeutic use of stem cell transplantation in ALS.

3. Describe the current clinical trials that are ongoing for stem cell transplantation in ALS.

Accreditation Statement:

This San Francisco Neurological Society is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The San Francisco Neurological Society takes responsibility for the content, quality and scientific integrity of this CME activity.

Designation Statement:

The San Francisco Neurological Society designates this educational activity for an estimated 1.0 AMA PRA Category 1 Credit(s) TM . This credit may also be applied to the CMA Certification in Continuing Medical Education.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s) TM issued by organizations accredited by the ACCME.

Who Should Attend:

Neurologists, neurosurgeons, neuroradiologists, neuropsychologists, residents, nurses, and other physicians interested in research and clinical advances in the neurosciences.

Registration Fees:

(Early Bird Registration discount by September 15, 2016)

SFNS Members:
Before September 15th: $100
After September 15th: $110

Before September 15th: $120
After September 15th: $130

Students, Residents and Fellows:
Before September 15th: $65
After September 15th: $65

Before September 15th: $100
After September 15th: $110

Industry (non-exhibitor):
Before September 15th: $150
After September 15th: $160